De-mannosylation of phosphorylated N-glycans

• US 9,689,015 B2
• Filed: 09/29/2011
• Issued: 06/27/2017
• Est. Priority Date: 09/29/2010
• Status: Active Grant

• Current Assignee: Oxyrane UK Limited, Universiteit Gent Vzw, VIB VZW
• Original Assignee: Oxyrane UK Limited
• Inventors: Piens, Kathleen Camilla Telesphore Alida Maria, Vervecken, Wouter
• Primary Examiner(s): RAGHU, GANAPATHIRAM
• Application Number:
  US13/876,730
• Publication Number:
  US 20130295603A1
• Time in Patent Office: 2,098 Days
• Field of Search: 435 681, 435 691, 435 694, 435 697, 435183, 43525411, 4352542
• CPC Class Codes: C12N 15/80 for fungi
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins
• CPC Class Codes: C12Y 302/01113 Mannosyl-oligosaccharide 1,2-alpha-mannosidase (3.2.1.113), i.e. alpha-1,2-mannosidase
• CPC Class Codes: Y02P 20/52 using catalysts, e.g. selective catalysts

Abstract

Methods for demannosylating phosphorylated N-glycans on a glycoprotein are described that use a mannosidase capable of hydrolyzing a terminal alpha-1,2 mannose linkage when the underlying mannose is phosphorylated.

Claims

1. A method for demannosylating phosphorylated N-glycans on a glycoprotein, said method comprising contacting in vitro a recombinant glycoprotein comprising a terminal alpha-1,2 mannose linkage in which the underlying mannose is phosphorylated with a mannosidase that hydrolyzes a terminal alpha-1,2 mannose linkage when the underlying mannose is phosphorylated, wherein the contacting results in hydrolysis of the terminal alpha-1,2 mannose linkage, to produce a demannosylated glycoprotein, wherein the mannosidase is:

(a) a wild-type glycoside hydrolase (GH)92 family polypeptide or a wild-type GH47 family polypeptide;

(b) a deletion variant that is the polypeptide of (a) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;

(c) a deletion variant that is the polypeptide of (a) or the variant of (b) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (a) or the variant of (b);

or

(d) a substitution variant that is the polypeptide of (a), the variant of (b), or the variant of (c), but with no more than 10 conservative substitutions.

2. The method of claim 1, wherein said mannosidase is from Aspergillus satoi.

3. The method of claim 1, wherein said mannosidase is from Cellulosimicrobium cellulans.

4. The method of claim 1, wherein the mannosidase comprises SEQ ID NO:

5.

5. The method of claim 1, wherein the mannosidase is of the GH47 family.

6. The method of claim 1, wherein the mannosidase comprises the amino acid sequence encoded by SEQ ID NO:

4.

7. The method of claim 1, wherein the mannosidase is of the GH92 family.

8. The method of claim 1, wherein the method further comprises isolating the demannosylated glycoprotein.

9. The method of claim 1, wherein the glycoprotein is a human protein.

10. The method of claim 1, wherein the glycoprotein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.

11. The method of claim 10, wherein the lysosomal protein is a lysosomal enzyme.

12. The method of claim 10, wherein the lysosomal enzyme is associated with a lysosomal storage disorder (LSD).

13. The method of claim 12, wherein the LSD is Fabry'"'"'s disease, mucopolysaccharidosis I, Farber disease, Gaucher disease, GM1-gangliosidosis, Tay-Sachs disease, Sandhoff disease, GM2 activator disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease, Scheie disease, Hunter disease, Sanfilippo disease, Morquio disease, Maroteaux-Lamy disease, hyaluronidase deficiency, aspartylglucosaminuria, fucosidosis, mannosidosis, Schindler disease, sialidosis type 1, Pompe disease, Pycnodysostosis, ceroid lipofuscinosis, cholesterol ester storage disease, Wolman disease, Multiple sulfatase deficiency, galactosialidosis, mucolipidosis, cystinosis, sialic acid storage disorder, chylomicron retention disease with Marinesco-Sjö

gren syndrome, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Danon disease, or Geleophysic dysplasia.